ClinicalTrials.gg
CompletedNCT01358877APHINITYUpdated Nov 28, 2025Results posted

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

A Phase 3 interventional study of 5-Fluorouracil and Carboplatin in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 546 sites in 42 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,804
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
3rd of 104
4,804 · median 100
Started
2011
with 2 others
Phase 3
23 of 104
2 open now
Registered
11th of 104
by date
Lead sponsor
20 of 104
Hoffmann-La Roche

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is one of 23 in phase 3, and was the 11th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non- operable primary invasive -positive carcinoma of the breast that is confirmed, and adequately excised
  • (ECOG) performance status less than or equal to (\</=) 1
  • Known hormone receptor status (estrogen receptor and progesterone receptor)
  • The interval between definitive surgery for breast cancer and the first dose of chemotherapy must be no more than 8 weeks (56 days). The first cycle of chemotherapy must be administered within 7 days of randomization or on Day 56, whichever occurs first
  • Baseline (LVEF) greater than or equal to (>/=) 55 percent (%) measured by echocardiogram (ECHO) or Multiple-Gated Acquisition (MUGA) Scan
  • Confirmed HER2 positive status
  • Completion of all necessary baseline laboratory and radiologic investigations prior to randomization
  • Women of and male participants with partners of childbearing potential must agree to use effective (as defined by the protocol) by the participant and/or partner for the duration of the study treatment and for at least 7 months after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • History of any prior (ipsi- and/or contralateral) invasive breast cancer
  • History of non-breast within the 5 years prior to study entry, except for carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin
  • Any "clinical" T4 tumor as defined by primary tumor/regional lymph nodes/distant (TNM), including inflammatory breast cancer
  • Any node-negative tumor
  • Any previous systemic chemotherapy for cancer or radiotherapy for cancer
  • Prior use of anti- therapy for any reason or other prior biologic or immunotherapy for cancer
  • Concurrent anti-cancer treatment in another trial
  • Serious cardiac or cardiovascular disease or condition
  • Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness
  • Abnormal laboratory tests immediately prior to randomization
  • Pregnant or lactating women
  • Sensitivity to any of the study medications or any of the ingredients or of these medications
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4,804 participants (actual)

Study arms

  • Experimental
    Pertuzumab + Trastuzumab + Chemotherapy

    Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).

    Drug: 5-Fluorouracil · Drug: Carboplatin · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel · Drug: Pertuzumab · Drug: Trastuzumab

  • Placebo comparator
    Placebo + Trastuzumab + Chemotherapy

    Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]).

    Drug: 5-Fluorouracil · Drug: Carboplatin · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel · Drug: Placebo · Drug: Trastuzumab

Interventions

  • 5-Fluorouracil will be administered as per the schedule specified in the respective arm.

  • Carboplatin will be administered as per the schedule specified in the respective arm.

  • Cyclophosphamide will be administered as per the schedule specified in the respective arm.

  • Docetaxel will be administered as per the schedule specified in the respective arm.

  • Doxorubicin will be administered as per the schedule specified in the respective arm.

  • Epirubicin will be administered as per the schedule specified in the respective arm.

  • Paclitaxel will be administered as per the schedule specified in the respective arm.

  • Pertuzumab will be administered as per the schedule specified in the respective arm.

    Also known as: Perjeta®

  • DrugPlacebo

    Placebo will be administered as per the schedule specified in the respective arm.

  • Trastuzumab will be administered as per the schedule specified in the respective arm.

    Also known as: Herceptin®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Percentage of participants with IDFS events (excluding SPNBC) is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (that is \[i.e.\], an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including ductal carcinoma in situ \[DCIS\] and lobular carcinoma in situ \[LCIS\]) and non-melanoma skin cancer were excluded as an event.

    Time frame: Randomization to the first occurrence of IDFS event (excluding SPNBC) (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)

  2. Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (excluding SPNBC) at 3 years is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event.

    Time frame: 3 years

Secondary outcomes

  1. Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    The Kaplan-Meier estimates of the percentage of participants who were IDFS event-free (excluding SPNBC) at 6, 8, and 10 years are reported. IDFS event was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, or contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event. Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.

    Time frame: 6, 8, and 10 years

  2. Percentage of Participants With IDFS Event (Including SPNBC), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Percentage of participants with IDFS events (including SPNBC) is reported. IDFS-SPNBC event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).

    Time frame: Randomization to the first occurrence of IDFS event (including SPNBC) (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)

  3. Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (including SPNBC) at 3 years is reported. IDFS-SPNBC was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).

    Time frame: 3 years

  4. Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Kaplan-Meier estimates of the percentage of participants who were IDFS event-free (including SPNBC) at 6, 8, and 10 years are reported. IDFS-SPNBC was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer, or SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site). Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.

    Time frame: 6, 8, and 10 years

  5. Percentage of Participants With Disease-Free Survival (DFS) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Percentage of participants with DFS event is reported. DFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS.

    Time frame: Randomization to the first occurrence of DFS event (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)

  6. Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Kaplan-Meier estimate of the percentage of participants who were DFS event-free at 3 years is reported. DFS was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS.

    Time frame: 3 years

  7. Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Kaplan-Meier estimates of the percentage of participants who were DFS event-free at 6, 8, and 10 years are reported. DFS was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer, SPNBC, or contralateral or ipsilateral DCIS. Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.

    Time frame: 6, 8, and 10 years

  8. Percentage of Participants Who Died, First Interim Overall Survival Analysis

    Percentage of participants who died due to any cause is reported.

    Time frame: Randomization until death due to any cause (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)

  9. Percentage of Participants Who Died, Final Overall Survival Analysis

    Percentage of participants who died due to any cause is reported.

    Time frame: Randomization until death due to any cause (median [range] follow-up: 11.3 [0-12.9] years)

  10. Kaplan-Meier Estimate of the Percentage of Participants Who Were Alive at 3 Years

    The Kaplan-Meier approach was used to estimate the percentage of participants who were alive at 3 years. Participants who were alive (including lost to follow-up) at the time of the analysis were censored at the date when they were last known to be alive.

    Time frame: 3 years

  11. Kaplan-Meier Estimate of the Percentage of Participants Who Were Alive at 6, 8, and 10 Years

    The Kaplan-Meier approach was used to estimate the percentage of participants who were alive at 6, 8, and 10 years. Participants who were alive (including lost to follow-up) at the time of the analysis were censored at the date when they were last known to be alive.

    Time frame: 6, 8, and 10 years

  12. Percentage of Participants With Recurrence-Free Interval (RFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Percentage of participants with RFI event is reported. RFI event was defined as local, regional or distant breast cancer recurrence.

    Time frame: Randomization until local, regional or distant breast cancer recurrence (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)

  13. Kaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Kaplan-Meier estimate of the percentage of participants who were RFI event-free at 3 years is reported. RFI event was defined as local, regional or distant breast cancer recurrence. Participants who had not had a recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.

    Time frame: 3 years

  14. Kaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Kaplan-Meier estimates of the percentage of participants who were RFI event-free at 6, 8, and 10 years are reported. RFI event was defined as local, regional or distant breast cancer recurrence. Participants who had not had a recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.

    Time frame: 6, 8, and 10 years

  15. Percentage of Participants With Distant Recurrence-Free Interval (DRFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Percentage of participants with DRFI event is reported. DRFI event was defined as distant breast cancer recurrence.

    Time frame: Randomization until distant breast cancer recurrence (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)

  16. Kaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Kaplan-Meier estimate of the percentage of participants who were DRFI event-free at 3 years is reported. DRFI event was defined as distant breast cancer recurrence. Participants who had not had a distant recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.

    Time frame: 3 years

  17. Kaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

    Kaplan-Meier estimates of the percentage of participants who were DRFI event-free at 6, 8, and 10 years are reported. DRFI event was defined as distant breast cancer recurrence. Participants who had not had a distant recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.

    Time frame: 6, 8, and 10 years

  18. Percentage of Participants With Primary Cardiac Event, Primary Analysis

    Primary cardiac event was defined as either: Heart Failure (New York Heart Association \[NYHA\] Class III or IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction (EF) points from baseline and to below 50 percent (%); or cardiac death. Cardiac death was defined as either definite cardiac death: due to heart failure, myocardial infarction, or documented primary arrhythmia; or probable cardiac death: sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology.

    Time frame: Baseline until data cut-off date 19 December 2016 (median [range] follow-up: 3.8 [0.1-4.9] years)

  19. Percentage of Participants With Primary Cardiac Event, Final Analysis

    Primary cardiac event was defined as either: Heart Failure (New York Heart Association \[NYHA\] Class III or IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction (EF) points from baseline and to below 50 percent (%); or cardiac death. Cardiac death was defined as either definite cardiac death: due to heart failure, myocardial infarction, or documented primary arrhythmia; or probable cardiac death: sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology.

    Time frame: Baseline until the end of follow-up (median [range] follow-up: 11.3 [0.1-12.9] years)

  20. Percentage of Participants With Secondary Cardiac Event, Primary Analysis

    Secondary cardiac event was defined as asymptomatic or mildly symptomatic (NYHA Class II) significant drop in LVEF (defined as an absolute decrease of at least 10 EF points from baseline and to below 50%), confirmed by a second LVEF assessment within approximately three weeks of the first significant LVEF assessment or confirmed by the Cardiac Advisory Board (CAB).

    Time frame: Baseline until data cut-off date 19 December 2016 (median [range] follow-up: 3.8 [0.1-4.9] years)

  21. Percentage of Participants With Secondary Cardiac Event, Final Analysis

    Secondary cardiac event was defined as asymptomatic or mildly symptomatic (NYHA Class II) significant drop in LVEF (defined as an absolute decrease of at least 10 EF points from baseline and to below 50%), confirmed by a second LVEF assessment within approximately three weeks of the first significant LVEF assessment or confirmed by the Cardiac Advisory Board (CAB).

    Time frame: Baseline until the end of follow-up (median [range] follow-up: 11.3 [0.1-12.9] years)

  22. Change From Baseline in LVEF to Worst Post-Baseline Value, Primary Analysis

    LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. Baseline LVEF value and the maximum absolute decrease (worst value) in LVEF measurement from baseline were reported. LVEF was measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.

    Time frame: Baseline until data cut-off date 19 December 2016 (median [range] follow-up: 3.8 [0.1-4.9] years)

  23. Change From Baseline in LVEF to Worst Post-Baseline Value, Final Analysis

    LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. Baseline LVEF value and the maximum absolute decrease (worst value) in LVEF measurement from baseline were reported. LVEF was measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.

    Time frame: Baseline until the end of follow-up (median [range] follow-up: 11.3 [0.1-12.9] years)

  24. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Scale Score

    EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall quality of life (QOL) in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, used 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 global scores were linearly transformed on a scale of 0 to 100, with a high score indicating better GHS/QOL. Negative change from Baseline values indicated deterioration in QOL or functioning and positive values indicated improvement.

    Time frame: Baseline, Weeks 13, 25; end of treatment (EOT, 28 days after the last dose, up to Week 56); Follow-up (FU) Months 18, 24, 36

  25. Change From Baseline in EORTC QLQ-C30 Functioning Subscale Scores

    EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 functioning scores were linearly transformed on a scale of 0 to 100, with a high score indicating better functioning/support. Negative change from Baseline values indicated deterioration in functioning and positive values indicated improvement.

    Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36

  26. Change From Baseline in EORTC QLQ-C30 Disease/Treatment-Related Symptoms Subscale Scores

    EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 disease/treatment-related symptom scores were linearly transformed on a scale of 0 to 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicated improvement in symptoms and positive values indicated worsening of symptoms.

    Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36

  27. Change From Baseline in EORTC QLQ-C30 Financial Difficulties Subscale Scores

    EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 financial difficulties scores were linearly transformed on a scale of 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicated improvement in financial difficulties and positive values indicated worsening of financial difficulties.

    Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36

  28. Change From Baseline in European Organisation for Research and Treatment of Cancer - Breast Cancer Module Quality of Life (EORTC QLQ-BR23) Functional Scale Score

    EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.

    Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36

  29. Change From Baseline in EORTC QLQ-BR23 Symptom Scale Score

    EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for symptom scale indicated high level of symptomatology/problems/greater degree of symptoms. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.

    Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36

  30. Percentage of Participants With Response for European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Mobility Domain

    EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in mobility domain was reported: I have no problems in walking about; I have some problems in walking about; and I am confined to bed. Response percentages may not add up to 100% due to data rounding.

    Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36

  31. Percentage of Participants With Response for EQ-5D-3L Questionnaire: Self-Care Domain

    EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in self-care domain was reported: I have no problems with self-care; I have some problems washing or dressing myself; and I am unable to wash or dress myself. Response percentages may not add up to 100% due to data rounding.

    Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36

  32. Percentage of Participants With Response for EQ-5D-3L Questionnaire: Usual Activities Domain

    EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in usual activities domain was reported: I have no problems with performing my usual activities; I have some problems with performing my usual activities; and I am unable to perform my usual activities. Response percentages may not add up to 100% due to data rounding.

    Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36

  33. Percentage of Participants With Response for EQ-5D-3L Questionnaire: Pain/Discomfort Domain

    EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in pain/discomfort domain was reported: I have no pain or discomfort; I have moderate pain or discomfort; and I have extreme pain or discomfort. Response percentages may not add up to 100% due to data rounding.

    Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36

  34. Percentage of Participants With Response for EQ-5D-3L Questionnaire: Anxiety/Depression Domain

    EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in anxiety/depression domain was reported: I am not anxious or depressed; I am moderately anxious or depressed; and I am extremely anxious or depressed. Response percentages may not add up to 100% due to data rounding.

    Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36

  35. Trough Serum Concentration (Cmin) of Pertuzumab

    Time frame: Cycles 1, 10 and 15 (Cycle length=21 days)

  36. Cmin of Trastuzumab

    Time frame: Cycles 1, 10 and 15 (Cycle length=21 days)

  37. Peak Serum Concentration (Cmax) of Pertuzumab

    Time frame: Cycles 1, 10 and 15 (Cycle length=21 days)

  38. Cmax of Trastuzumab

    Time frame: Cycles 1, 10 and 15 (Cycle length=21 days)

07

Results

Posted Jan 5, 2018

Participant flow

Overall, 4804 patients were randomized in the study, 2400 in the Pertuzumab arm and 2404 in the Placebo arm.

Participant flow — Overall Study
MilestonePertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Started24002404
Received at least 1 dose of pertuzumab234024
Received any study treatment except for pertuzumab382367
Entered follow-up23692381
Completed13611316
Not completed10391088
Withdrew: Withdrawal by subject475466
Withdrew: Recurrence of disease181269
Withdrew: Lost to follow-up181176
Withdrew: Death4146
Withdrew: Adverse event3942
Withdrew: Physician decision4332
Withdrew: Contralateral breast cancer4228
Withdrew: Reason not specified3729

Outcome measures

SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

The Kaplan-Meier estimates of the percentage of participants who were IDFS event-free (excluding SPNBC) at 6, 8, and 10 years are reported. IDFS event was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, or contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event. Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.

Time frame:
6, 8, and 10 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
6 Years90.56 (89.35 to 91.77)87.76 (86.40 to 89.13)
8 Years88.43 (87.10 to 89.76)85.76 (84.32 to 87.21)
10 Years87.17 (85.77 to 88.57)83.82 (82.29 to 85.36)
SecondaryPercentage of Participants With IDFS Event (Including SPNBC), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Percentage of participants with IDFS events (including SPNBC) is reported. IDFS-SPNBC event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).

Time frame:
Randomization to the first occurrence of IDFS event (including SPNBC) (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Reported as:
Number · percentage of participants
Percentage of Participants With IDFS Event (Including SPNBC), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Percentage of Participants With IDFS Event (Including SPNBC), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings7.99.6
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Log Rank · p = 0.0430 (Statistical significance was controlled at a two-sided alpha level of 0.05.) · Hazard ratio (hr): 0.82 · 95% CI 0.68 to 0.99Hazard ratio was estimated by Cox regression.
SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (including SPNBC) at 3 years is reported. IDFS-SPNBC was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).

Time frame:
3 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings93.50 (92.49 to 94.51)92.51 (91.43 to 93.58)
SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Kaplan-Meier estimates of the percentage of participants who were IDFS event-free (including SPNBC) at 6, 8, and 10 years are reported. IDFS-SPNBC was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer, or SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site). Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.

Time frame:
6, 8, and 10 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
6 Years89.31 (88.03 to 90.59)86.42 (85.00 to 87.44)
8 Years87.08 (85.69 to 88.48)83.82 (82.29 to 85.34)
10 Years85.23 (83.74 to 86.71)81.31 (79.69 to 82.93)
SecondaryPercentage of Participants With Disease-Free Survival (DFS) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Percentage of participants with DFS event is reported. DFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS.

Time frame:
Randomization to the first occurrence of DFS event (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease-Free Survival (DFS) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Percentage of Participants With Disease-Free Survival (DFS) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings8.09.8
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Log Rank · p = 0.0327 (Statistical significance was controlled at a two-sided alpha level of 0.05.) · Hazard ratio (hr): 0.81 · 95% CI 0.67 to 0.98Hazard ratio was estimated by Cox regression.
SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Kaplan-Meier estimate of the percentage of participants who were DFS event-free at 3 years is reported. DFS was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS.

Time frame:
3 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings93.42 (92.40 to 94.43)92.29 (91.21 to 93.38)
SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Kaplan-Meier estimates of the percentage of participants who were DFS event-free at 6, 8, and 10 years are reported. DFS was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer, SPNBC, or contralateral or ipsilateral DCIS. Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.

Time frame:
6, 8, and 10 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
6 Years88.99 (87.69 to 90.29)86.03 (84.59 to 87.47)
8 Years86.92 (85.52 to 88.32)83.19 (81.64 to 88.74)
10 Years85.01 (83.52 to 86.50)80.54 (78.89 to 82.19)
SecondaryPercentage of Participants Who Died, First Interim Overall Survival Analysis

Percentage of participants who died due to any cause is reported.

Time frame:
Randomization until death due to any cause (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died, First Interim Overall Survival Analysis
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Percentage of Participants Who Died, First Interim Overall Survival Analysis3.33.7
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Log Rank · p = 0.4673 (The O'Brien-Fleming stopping boundary of the Lan-DeMets alpha-spending function for the first interim OS analysis was HR\<0.52; p\<0.00001.) · Hazard ratio (hr): 0.89 · 95% CI 0.66 to 1.21Hazard ratio was estimated by Cox regression.
SecondaryPercentage of Participants Who Died, Final Overall Survival Analysis

Percentage of participants who died due to any cause is reported.

Time frame:
Randomization until death due to any cause (median [range] follow-up: 11.3 [0-12.9] years)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died, Final Overall Survival Analysis
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Percentage of Participants Who Died, Final Overall Survival Analysis8.5410.27
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Log Rank · p = 0.0441 (The p-value threshold according to the alpha-spending function at this final analysis was 0.0496.) · Hazard ratio (hr): 0.83 · 95% CI 0.69 to 1.00Hazard ratio was estimated by Cox regression.
SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Were Alive at 3 Years

The Kaplan-Meier approach was used to estimate the percentage of participants who were alive at 3 years. Participants who were alive (including lost to follow-up) at the time of the analysis were censored at the date when they were last known to be alive.

Time frame:
3 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were Alive at 3 Years
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Kaplan-Meier Estimate of the Percentage of Participants Who Were Alive at 3 Years97.65 (97.03 to 98.27)97.67 (97.06 to 98.29)
SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Were Alive at 6, 8, and 10 Years

The Kaplan-Meier approach was used to estimate the percentage of participants who were alive at 6, 8, and 10 years. Participants who were alive (including lost to follow-up) at the time of the analysis were censored at the date when they were last known to be alive.

Time frame:
6, 8, and 10 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were Alive at 6, 8, and 10 Years
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
6 Years94.78 (93.85 to 95.71)93.93 (92.93 to 94.92)
8 Years92.74 (91.66 to 93.82)91.96 (90.83 to 93.09)
10 Years91.55 (90.38 to 92.71)89.79 (88.53 to 91.06)
SecondaryPercentage of Participants With Recurrence-Free Interval (RFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Percentage of participants with RFI event is reported. RFI event was defined as local, regional or distant breast cancer recurrence.

Time frame:
Randomization until local, regional or distant breast cancer recurrence (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Reported as:
Number · percentage of participants
Percentage of Participants With Recurrence-Free Interval (RFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Percentage of Participants With Recurrence-Free Interval (RFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings5.87.2
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Log Rank · p = 0.0430 · Hazard ratio (hr): 0.79 · 95% CI 0.63 to 0.99Hazard ratio was estimated by Cox regression.
SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Kaplan-Meier estimate of the percentage of participants who were RFI event-free at 3 years is reported. RFI event was defined as local, regional or distant breast cancer recurrence. Participants who had not had a recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.

Time frame:
3 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Kaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings95.18 (94.30 to 96.06)94.27 (93.32 to 95.21)
SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Kaplan-Meier estimates of the percentage of participants who were RFI event-free at 6, 8, and 10 years are reported. RFI event was defined as local, regional or distant breast cancer recurrence. Participants who had not had a recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.

Time frame:
6, 8, and 10 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
6 Years92.49 (91.40 to 93.59)89.91 (88.66 to 91.16)
8 Years92.11 (90.99 to 93.23)88.88 (87.59 to 90.18)
10 Years91.87 (90.74 to 93.00)88.10 (86.76 to 89.44)
SecondaryPercentage of Participants With Distant Recurrence-Free Interval (DRFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Percentage of participants with DRFI event is reported. DRFI event was defined as distant breast cancer recurrence.

Time frame:
Randomization until distant breast cancer recurrence (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Reported as:
Number · percentage of participants
Percentage of Participants With Distant Recurrence-Free Interval (DRFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Percentage of Participants With Distant Recurrence-Free Interval (DRFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings5.06.0
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Log Rank · p = 0.1007 · Hazard ratio (hr): 0.82 · 95% CI 0.64 to 1.04Hazard ratio was estimated by Cox regression.
SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Kaplan-Meier estimate of the percentage of participants who were DRFI event-free at 3 years is reported. DRFI event was defined as distant breast cancer recurrence. Participants who had not had a distant recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.

Time frame:
3 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Kaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings95.70 (94.86 to 96.53)95.13 (94.25 to 96.00)
SecondaryKaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Kaplan-Meier estimates of the percentage of participants who were DRFI event-free at 6, 8, and 10 years are reported. DRFI event was defined as distant breast cancer recurrence. Participants who had not had a distant recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.

Time frame:
6, 8, and 10 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
6 Years93.37 (92.34 to 94.40)91.57 (90.42 to 92.72)
8 Years92.94 (91.88 to 94.01)90.69 (89.49 to 91.89)
10 Years92.85 (91.78 to 93.92)90.01 (88.77 to 91.25)
SecondaryPercentage of Participants With Primary Cardiac Event, Primary Analysis

Primary cardiac event was defined as either: Heart Failure (New York Heart Association \[NYHA\] Class III or IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction (EF) points from baseline and to below 50 percent (%); or cardiac death. Cardiac death was defined as either definite cardiac death: due to heart failure, myocardial infarction, or documented primary arrhythmia; or probable cardiac death: sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology.

Time frame:
Baseline until data cut-off date 19 December 2016 (median [range] follow-up: 3.8 [0.1-4.9] years)
Reported as:
Number · percentage of participants
Percentage of Participants With Primary Cardiac Event, Primary Analysis
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Primary Cardiac Event (Composite)0.70.3
Heart Failure and LVEF Decline0.60.2
Cardiac Death (Definite or Probable)0.10.1
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Treatment difference: 0.4 · 95% CI 0.0 to 0.8The difference in percentage of participants with a primary cardiac event between the pertuzumab and placebo arms. The 95% confidence interval (CI) was estimated using Hauck-Anderson correction.
SecondaryPercentage of Participants With Primary Cardiac Event, Final Analysis

Primary cardiac event was defined as either: Heart Failure (New York Heart Association \[NYHA\] Class III or IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction (EF) points from baseline and to below 50 percent (%); or cardiac death. Cardiac death was defined as either definite cardiac death: due to heart failure, myocardial infarction, or documented primary arrhythmia; or probable cardiac death: sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology.

Time frame:
Baseline until the end of follow-up (median [range] follow-up: 11.3 [0.1-12.9] years)
Reported as:
Number · percentage of participants
Percentage of Participants With Primary Cardiac Event, Final Analysis
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Primary Cardiac Event (Composite)0.90.5
Heart Failure and LVEF Decline0.80.3
Cardiac Death (Definite or Probable)0.10.2
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Treatment difference: 0.4 · 95% CI -0.1 to 0.9The difference in percentage of participants with a primary cardiac event between the pertuzumab and placebo arms. The 95% confidence interval (CI) was estimated using Hauck-Anderson correction.
SecondaryPercentage of Participants With Secondary Cardiac Event, Primary Analysis

Secondary cardiac event was defined as asymptomatic or mildly symptomatic (NYHA Class II) significant drop in LVEF (defined as an absolute decrease of at least 10 EF points from baseline and to below 50%), confirmed by a second LVEF assessment within approximately three weeks of the first significant LVEF assessment or confirmed by the Cardiac Advisory Board (CAB).

Time frame:
Baseline until data cut-off date 19 December 2016 (median [range] follow-up: 3.8 [0.1-4.9] years)
Reported as:
Number · percentage of participants
Percentage of Participants With Secondary Cardiac Event, Primary Analysis
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Percentage of Participants With Secondary Cardiac Event, Primary Analysis2.72.8
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Treatment difference: -0.1 · 95% CI -1.0 to 0.995% CI was estimated using Hauck-Anderson correction.
SecondaryPercentage of Participants With Secondary Cardiac Event, Final Analysis

Secondary cardiac event was defined as asymptomatic or mildly symptomatic (NYHA Class II) significant drop in LVEF (defined as an absolute decrease of at least 10 EF points from baseline and to below 50%), confirmed by a second LVEF assessment within approximately three weeks of the first significant LVEF assessment or confirmed by the Cardiac Advisory Board (CAB).

Time frame:
Baseline until the end of follow-up (median [range] follow-up: 11.3 [0.1-12.9] years)
Reported as:
Number · percentage of participants
Percentage of Participants With Secondary Cardiac Event, Final Analysis
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Percentage of Participants With Secondary Cardiac Event, Final Analysis2.93.0
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Treatment difference: -0.1 · 95% CI -1.1 to 0.995% CI was estimated using Hauck-Anderson correction.
SecondaryChange From Baseline in LVEF to Worst Post-Baseline Value, Primary Analysis

LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. Baseline LVEF value and the maximum absolute decrease (worst value) in LVEF measurement from baseline were reported. LVEF was measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.

Time frame:
Baseline until data cut-off date 19 December 2016 (median [range] follow-up: 3.8 [0.1-4.9] years)
Reported as:
Mean · percentage of blood pumped out
Change From Baseline in LVEF to Worst Post-Baseline Value, Primary Analysis
percentage of blood pumped outPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline65.2 ± 5.965.3 ± 6.1
Change to Worst Value-7.5 ± 6.6-7.6 ± 6.7
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Treatment difference: 0.1 · 95% CI -0.3 to 0.595% CI was estimated using Hauck-Anderson correction.
SecondaryChange From Baseline in LVEF to Worst Post-Baseline Value, Final Analysis

LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. Baseline LVEF value and the maximum absolute decrease (worst value) in LVEF measurement from baseline were reported. LVEF was measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.

Time frame:
Baseline until the end of follow-up (median [range] follow-up: 11.3 [0.1-12.9] years)
Reported as:
Mean · percentage of blood pumped out
Change From Baseline in LVEF to Worst Post-Baseline Value, Final Analysis
percentage of blood pumped outPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline65.2 ± 5.965.3 ± 6.1
Change to Worst Value-8.6 ± 6.8-8.6 ± 7.0
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Treatment difference: 0.0 · 95% CI -0.4 to 0.495% CI was estimated using Hauck-Anderson correction.
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Scale Score

EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall quality of life (QOL) in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, used 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 global scores were linearly transformed on a scale of 0 to 100, with a high score indicating better GHS/QOL. Negative change from Baseline values indicated deterioration in QOL or functioning and positive values indicated improvement.

Time frame:
Baseline, Weeks 13, 25; end of treatment (EOT, 28 days after the last dose, up to Week 56); Follow-up (FU) Months 18, 24, 36
Reported as:
Mean · units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Scale Score
units on a scalePertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline72.9 ± 19.772.5 ± 19.7
Change at Week 13-11.2 ± 22.8-10.2 ± 22.6
Change at Week 25-4.4 ± 21.6-2.9 ± 21.0
Change at EOT-3.1 ± 21.9-1.1 ± 21.8
Change at FU Month 181.9 ± 21.51.3 ± 22.2
Change at FU Month 242.2 ± 22.12.4 ± 22.1
Change at FU Month 362.8 ± 21.41.8 ± 22.5
SecondaryChange From Baseline in EORTC QLQ-C30 Functioning Subscale Scores

EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 functioning scores were linearly transformed on a scale of 0 to 100, with a high score indicating better functioning/support. Negative change from Baseline values indicated deterioration in functioning and positive values indicated improvement.

Time frame:
Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Reported as:
Mean · units on a scale
Change From Baseline in EORTC QLQ-C30 Functioning Subscale Scores
units on a scalePertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline: Physical89.6 ± 12.989.1 ± 13.4
Change at Week 13: Physical-10.7 ± 17.2-10.6 ± 17.7
Change at Week 25: Physical-4.6 ± 14.5-4.3 ± 14.5
Change at EOT: Physical-4.1 ± 14.7-3.2 ± 14.9
Change at FU Month 18: Physical-0.9 ± 13.5-0.9 ± 14.5
Change at FU Month 24: Physical-0.4 ± 13.8-0.3 ± 14.5
Change at FU Month 36: Physical-0.3 ± 14.1-0.1 ± 13.9
Baseline: Role79.8 ± 24.779.4 ± 25.2
Change at Week 13: Role-8.0 ± 28.6-8.5 ± 29.5
Change at Week 25: Role-0.7 ± 26.40.4 ± 27.8
Change at EOT: Role0.4 ± 27.82.3 ± 28.1
Change at FU Month 18: Role6.1 ± 26.55.7 ± 28.9
Change at FU Month 24: Role7.3 ± 26.86.9 ± 28.2
Change at FU Month 36: Role7.9 ± 26.47.6 ± 27.9
Baseline: Social81.9 ± 22.980.6 ± 24.1
Change at Week 13: Social-8.7 ± 25.8-7.8 ± 27.1
Change at Week 25: Social-2.2 ± 24.5-0.7 ± 26.3
Change at EOT: Social0.0 ± 25.21.2 ± 26.3
Change at FU Month 18: Social5.0 ± 23.84.8 ± 26.7
Change at FU Month 24: Social5.5 ± 24.86.5 ± 26.6
Change at FU Month 36: Social6.6 ± 24.97.1 ± 27.3
Baseline: Cognitive88.8 ± 16.687.9 ± 17.9
Change at Week 13: Cognitive-9.1 ± 20.5-9.0 ± 21.4
Change at Week 25: Cognitive-7.6 ± 20.4-7.0 ± 20.8
Change at EOT: Cognitive-7.7 ± 20.6-7.2 ± 21.4
Change at FU Month 18: Cognitive-6.1 ± 19.6-5.8 ± 21.2
Change at FU Month 24: Cognitive-6.2 ± 20.5-5.5 ± 21.7
Change at FU Month 36: Cognitive-5.4 ± 20.6-4.9 ± 21.8
Baseline: Emotional72.8 ± 22.471.3 ± 22.7
Change at Week 13: Emotional3.3 ± 22.22.9 ± 22.5
Change at Week 25: Emotional5.1 ± 22.75.9 ± 22.2
Change at EOT: Emotional5.6 ± 23.26.2 ± 23.4
Change at FU Month 18: Emotional7.7 ± 23.47.6 ± 23.4
Change at FU Month 24: Emotional7.8 ± 23.38.5 ± 24.2
Change at FU Month 36: Emotional7.8 ± 23.88.4 ± 24.4
SecondaryChange From Baseline in EORTC QLQ-C30 Disease/Treatment-Related Symptoms Subscale Scores

EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 disease/treatment-related symptom scores were linearly transformed on a scale of 0 to 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicated improvement in symptoms and positive values indicated worsening of symptoms.

Time frame:
Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Reported as:
Mean · units on a scale
Change From Baseline in EORTC QLQ-C30 Disease/Treatment-Related Symptoms Subscale Scores
units on a scalePertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline: Diarrhea5.2 ± 14.45.1 ± 13.5
Change at Week 13: Diarrhea22.3 ± 29.89.2 ± 23.9
Change at Week 25: Diarrhea13.2 ± 26.53.3 ± 19.8
Change at EOT: Diarrhea12.2 ± 26.92.9 ± 20.0
Change at FU Month 18: Diarrhea-0.5 ± 17.70.2 ± 17.5
Change at FU Month 24: Diarrhea-0.8 ± 17.40.2 ± 18.3
Change at FU Month 36: Diarrhea-0.8 ± 16.50.3 ± 16.9
Baseline: Fatigue22.4 ± 19.723.2 ± 20.5
Change at Week 13: Fatigue16.1 ± 24.316.2 ± 24.4
Change at Week 25: Fatigue7.8 ± 22.56.6 ± 22.3
Change at EOT: Fatigue7.1 ± 23.05.2 ± 23.0
Change at FU Month 18: Fatigue1.1 ± 21.71.2 ± 22.5
Change at FU Month 24: Fatigue0.4 ± 22.00.4 ± 22.6
Change at FU Month 36: Fatigue-0.2 ± 21.80.6 ± 22.8
Baseline: Dyspnea6.8 ± 15.58.0 ± 17.1
Change at Week 13: Dyspnea12.3 ± 23.814.6 ± 26.4
Change at Week 25: Dyspnea6.3 ± 19.96.4 ± 22.1
Change at EOT: Dyspnea6.6 ± 20.56.5 ± 22.5
Change at FU Month 18: Dyspnea5.9 ± 21.05.0 ± 21.5
Change at FU Month 24: Dyspnea5.1 ± 20.55.3 ± 22.4
Change at FU Month 36: Dyspnea5.1 ± 20.55.3 ± 22.3
Baseline: Appetite Loss8.5 ± 18.29.1 ± 18.7
Change at Week 13: Appetite Loss13.6 ± 29.27.7 ± 27.9
Change at Week 25: Appetite Loss5.2 ± 25.10.3 ± 22.4
Change at EOT: Appetite Loss3.0 ± 24.5-0.9 ± 22.6
Change at FU Month 18: Appetite Loss-3.0 ± 20.1-3.1 ± 21.1
Change at FU Month 24: Appetite Loss-3.2 ± 20.6-3.3 ± 21.0
Change at FU Month 36: Appetite Loss-3.0 ± 20.4-2.7 ± 21.2
Baseline: Insomnia25.3 ± 27.427.3 ± 28.5
Change at Week 13: Insomnia6.3 ± 30.35.1 ± 32.2
Change at Week 25: Insomnia4.3 ± 30.62.0 ± 31.8
Change at EOT: Insomnia3.2 ± 31.00.9 ± 32.8
Change at FU Month 18: Insomnia-0.1 ± 31.10.4 ± 32.4
Change at FU Month 24: Insomnia-1.5 ± 31.3-1.1 ± 32.9
Change at FU Month 36: Insomnia-0.3 ± 31.1-0.5 ± 33.5
Baseline: N/V2.7 ± 8.23.1 ± 9.4
Change at Week 13: N/V5.6 ± 15.73.7 ± 14.5
Change at Week 25: N/V1.1 ± 11.80.5 ± 12.4
Change at EOT: N/V1.6 ± 12.70.8 ± 13.2
Change at FU Month 18: N/V-0.2 ± 10.5-0.4 ± 12.1
Change at FU Month 24: N/V0.0 ± 10.7-0.1 ± 11.8
Change at FU Month 36: N/V0.3 ± 11.00.2 ± 11.7
Baseline: Constipation8.7 ± 19.110.0 ± 19.8
Change at Week 13: Constipation1.4 ± 23.54.1 ± 25.6
Change at Week 25: Constipation-0.7 ± 21.80.2 ± 22.8
Change at EOT: Constipation0.1 ± 22.40.9 ± 23.3
Change at FU Month 18: Constipation3.0 ± 23.31.5 ± 23.8
Change at FU Month 24: Constipation2.1 ± 23.10.6 ± 22.9
Change at FU Month 36: Constipation2.1 ± 22.91.5 ± 22.7
Baseline: Pain18.8 ± 21.419.6 ± 22.1
Change at Week 13: Pain2.3 ± 25.45.0 ± 26.1
Change at Week 25: Pain1.4 ± 24.11.4 ± 24.9
Change at EOT: Pain0.1 ± 24.70.5 ± 25.8
Change at FU Month 18: Pain-1.3 ± 23.3-0.5 ± 25.8
Change at FU Month 24: Pain-1.6 ± 24.2-2.2 ± 25.6
Change at FU Month 36: Pain-2.6 ± 24.4-2.3 ± 25.0
SecondaryChange From Baseline in EORTC QLQ-C30 Financial Difficulties Subscale Scores

EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 financial difficulties scores were linearly transformed on a scale of 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicated improvement in financial difficulties and positive values indicated worsening of financial difficulties.

Time frame:
Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Reported as:
Mean · units on a scale
Change From Baseline in EORTC QLQ-C30 Financial Difficulties Subscale Scores
units on a scalePertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline20.3 ± 28.722.1 ± 30.0
Change at Week 133.1 ± 26.11.7 ± 27.0
Change at Week 252.3 ± 26.8-0.3 ± 26.9
Change at EOT-0.2 ± 27.6-1.5 ± 27.2
Change at FU Month 18-4.1 ± 27.9-5.1 ± 27.5
Change at FU Month 24-5.2 ± 28.6-6.9 ± 29.3
Change at FU Month 36-7.1 ± 28.5-8.3 ± 28.3
SecondaryChange From Baseline in European Organisation for Research and Treatment of Cancer - Breast Cancer Module Quality of Life (EORTC QLQ-BR23) Functional Scale Score

EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.

Time frame:
Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Reported as:
Mean · units on a scale
Change From Baseline in European Organisation for Research and Treatment of Cancer - Breast Cancer Module Quality of Life (EORTC QLQ-BR23) Functional Scale Score
units on a scalePertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline: Body Image79.7 ± 23.578.9 ± 23.7
Change at Week 13: Body Image-12.9 ± 24.7-13.9 ± 25.2
Change at Week 25: Body Image-7.6 ± 23.8-7.3 ± 23.4
Change at EOT: Body Image-4.9 ± 23.7-6.0 ± 24.6
Change at FU Month 18: Body Image-0.1 ± 23.3-1.3 ± 23.3
Change at FU Month 24: Body Image0.5 ± 23.60.1 ± 23.5
Change at FU Month 36: Body Image1.7 ± 24.40.7 ± 24.6
Baseline: Sexual Enjoyment54.0 ± 30.855.0 ± 30.7
Change at Week 13: Sexual Enjoyment-16.5 ± 28.4-13.1 ± 27.2
Change at Week 25: Sexual Enjoyment-11.9 ± 26.8-7.9 ± 26.5
Change at EOT: Sexual Enjoyment-10.7 ± 27.5-8.0 ± 27.7
Change at FU Month 18: Sexual Enjoyment-4.2 ± 28.5-6.7 ± 26.5
Change at FU Month 24: Sexual Enjoyment-6.0 ± 28.4-5.0 ± 27.6
Change at FU Month 36: Sexual Enjoyment-5.3 ± 28.1-6.0 ± 26.8
Baseline: Sexual Function19.6 ± 23.820.8 ± 24.3
Change at Week 13: Sexual Function-5.6 ± 20.5-6.6 ± 20.7
Change at Week 25: Sexual Function-2.6 ± 20.8-2.3 ± 20.9
Change at EOT: Sexual Function-1.0 ± 20.8-1.4 ± 21.2
Change at FU Month 18: Sexual Function2.5 ± 22.81.4 ± 21.7
Change at FU Month 24: Sexual Function2.8 ± 22.91.8 ± 22.7
Change at FU Month 36: Sexual Function2.6 ± 24.01.6 ± 23.6
Baseline: FP51.3 ± 31.750.5 ± 31.5
Change at Week 13: FP3.1 ± 30.21.8 ± 31.9
Change at Week 25: FP6.3 ± 31.15.4 ± 31.2
Change at EOT: FP7.7 ± 32.26.9 ± 31.8
Change at FU Month 18: FP12.9 ± 32.010.5 ± 32.0
Change at FU Month 24 : FP13.7 ± 32.912.9 ± 32.9
Change at FU Month 36: FP14.7 ± 34.113.6 ± 32.9
SecondaryChange From Baseline in EORTC QLQ-BR23 Symptom Scale Score

EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for symptom scale indicated high level of symptomatology/problems/greater degree of symptoms. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.

Time frame:
Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Reported as:
Mean · units on a scale
Change From Baseline in EORTC QLQ-BR23 Symptom Scale Score
units on a scalePertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline:Systemic SE9.5 ± 10.910.2 ± 11.2
Change at Week 13: Systemic SE21.1 ± 17.521.7 ± 17.9
Change at Week 25: Systemic SE9.2 ± 14.28.2 ± 14.2
Change at EOT: Systemic SE8.3 ± 15.47.5 ± 14.8
Change at FU Month 18: Systemic SE4.4 ± 12.85.5 ± 13.4
Change at FU Month 24: Systemic SE4.1 ± 13.24.9 ± 13.7
Change at FU Month 36: Systemic SE4.5 ± 13.65.2 ± 13.8
Baseline: Hair Loss26.4 ± 32.822.1 ± 29.0
Change at Week 13: Hair Loss17.3 ± 43.621.2 ± 37.8
Change at Week 25: Hair Loss8.3 ± 38.014.5 ± 38.4
Change at EOT: Hair Loss10.9 ± 40.117.9 ± 39.8
Change at FU Month 18: Hair Loss-7.0 ± 36.03.2 ± 34.9
Change at FU Month 24: Hair Loss-4.1 ± 39.30.7 ± 36.0
Change at FU Month 36: Hair Loss-5.6 ± 42.32.4 ± 34.7
Baseline: Arm Symptoms21.6 ± 19.121.7 ± 19.2
Change at Week 13: Arm Symptoms-4.7 ± 20.8-2.1 ± 21.5
Change at Week 25: Arm Symptoms-2.9 ± 21.3-2.3 ± 21.7
Change at EOT: Arm Symptoms-3.5 ± 21.5-3.4 ± 21.4
Change at FU Month 18: Arm Symptoms-4.0 ± 21.8-3.9 ± 22.5
Change at FU Month 24: Arm Symptoms-5.1 ± 21.6-5.0 ± 22.3
Change at FU Month 36: Arm Symptoms-5.9 ± 21.8-4.7 ± 22.4
Baseline: Breast Symptoms19.5 ± 17.520.4 ± 17.7
Change at Week 13: Breast Symptoms-5.0 ± 18.4-5.2 ± 18.0
Change at Week 25: Breast Symptoms1.9 ± 20.7-0.4 ± 20.6
Change at EOT: Breast Symptoms-0.6 ± 20.2-3.8 ± 19.7
Change at FU Month 18: Breast Symptoms-3.0 ± 18.7-5.9 ± 18.8
Change at FU Month 24: Breast Symptoms-6.4 ± 18.4-7.3 ± 18.7
Change at FU Month 36: Breast Symptoms-7.3 ± 18.8-7.9 ± 19.0
SecondaryPercentage of Participants With Response for European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Mobility Domain

EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in mobility domain was reported: I have no problems in walking about; I have some problems in walking about; and I am confined to bed. Response percentages may not add up to 100% due to data rounding.

Time frame:
Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Reported as:
Number · percentage of participants
Percentage of Participants With Response for European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Mobility Domain
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline: No problems93.892.9
Baseline: Some problems6.26.9
Baseline: Confined to bed0.00.2
Week 13: No problems77.574.8
Week 13: Some problems22.124.8
Week 13: Confined to bed0.40.4
Week 25: No problems83.882.7
Week 25: Some problems16.117.2
Week 25: Confined to bed0.10.1
EOT: No problems85.184.9
EOT: Some problems14.814.9
EOT: Confined to bed0.10.2
FU Month 18: No problems88.887.0
FU Month 18: Some problems11.212.8
FU Month 18: Confined to bed0.10.2
FU Month 24: No problems87.887.7
FU Month 24: Some problems12.112.1
FU Month 24: Confined to bed0.10.1
FU Month 36: No problems88.587.8
FU Month 36: Some problems11.512.1
FU Month 36: Confined to bed0.00.1
SecondaryPercentage of Participants With Response for EQ-5D-3L Questionnaire: Self-Care Domain

EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in self-care domain was reported: I have no problems with self-care; I have some problems washing or dressing myself; and I am unable to wash or dress myself. Response percentages may not add up to 100% due to data rounding.

Time frame:
Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Reported as:
Number · percentage of participants
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Self-Care Domain
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline: No problems89.790.7
Baseline: Some problems10.09.1
Baseline: Unable0.30.2
Week 13: No problems94.393.2
Week 13: Some problems5.36.4
Week 13: Unable0.40.4
Week 25: No problems95.595.0
Week 25: Some problems4.34.7
Week 25: Unable0.10.3
EOT: No problems95.495.8
EOT: Some problems4.44.0
EOT: Unable0.20.2
FU Month 18: No problems97.296.0
FU Month 18: Some problems2.63.6
FU Month 18: Unable0.20.3
FU Month 24: No problems96.996.3
FU Month 24: Some problems2.83.5
FU Month 24: Unable0.30.3
FU Month 36: No problems97.396.5
FU Month 36: Some problems2.53.2
FU Month 36: Unable0.20.3
SecondaryPercentage of Participants With Response for EQ-5D-3L Questionnaire: Usual Activities Domain

EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in usual activities domain was reported: I have no problems with performing my usual activities; I have some problems with performing my usual activities; and I am unable to perform my usual activities. Response percentages may not add up to 100% due to data rounding.

Time frame:
Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Reported as:
Number · percentage of participants
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Usual Activities Domain
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline: No problems67.466.1
Baseline: Some problems30.432.2
Baseline: Unable2.21.7
Week 13: No problems56.854.1
Week 13: Some problems40.143.0
Week 13: Unable3.12.9
Week 25: No problems66.565.8
Week 25: Some problems32.232.7
Week 25: Unable1.21.4
EOT: No problems72.472.5
EOT: Some problems26.326.6
EOT: Unable1.30.9
FU Month 18: No problems78.576.3
FU Month 18: Some problems20.623.0
FU Month 18: Unable0.90.7
FU Month 24: No problems78.779.1
FU Month 24: Some problems20.419.7
FU Month 24: Unable0.91.1
FU Month 36: No problems80.979.8
FU Month 36: Some problems18.319.4
FU Month 36: Unable0.70.8
SecondaryPercentage of Participants With Response for EQ-5D-3L Questionnaire: Pain/Discomfort Domain

EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in pain/discomfort domain was reported: I have no pain or discomfort; I have moderate pain or discomfort; and I have extreme pain or discomfort. Response percentages may not add up to 100% due to data rounding.

Time frame:
Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Reported as:
Number · percentage of participants
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Pain/Discomfort Domain
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline: No pain/discomfort49.049.0
Baseline: Moderate pain/discomfort50.049.7
Baseline: Extreme pain/discomfort1.01.3
Week 13: No pain/discomfort44.640.5
Week 13: Moderate pain/discomfort52.756.5
Week 13: Extreme pain/discomfort2.73.0
Week 25: No pain/discomfort44.343.7
Week 25: Moderate pain/discomfort53.354.4
Week 25: Extreme pain/discomfort2.41.9
EOT: No pain/discomfort49.350.0
EOT: Moderate pain/discomfort48.547.6
EOT: Extreme pain/discomfort2.22.4
FU Month 18: No pain/discomfort51.353.1
FU Month 18: Moderate pain/discomfort46.644.7
FU Month 18: Extreme pain/discomfort2.12.1
FU Month 24: No pain/discomfort56.756.0
FU Month 24: Moderate pain/discomfort41.341.5
FU Month 24: Extreme pain/discomfort1.92.5
FU Month 36: No pain/discomfort59.557.8
FU Month 36: Moderate pain/discomfort38.940.1
FU Month 36: Extreme pain/discomfort1.62.1
SecondaryPercentage of Participants With Response for EQ-5D-3L Questionnaire: Anxiety/Depression Domain

EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in anxiety/depression domain was reported: I am not anxious or depressed; I am moderately anxious or depressed; and I am extremely anxious or depressed. Response percentages may not add up to 100% due to data rounding.

Time frame:
Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Reported as:
Number · percentage of participants
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Anxiety/Depression Domain
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Baseline: Not anxious/depress47.144.7
Baseline: Moderate anxious/depress49.450.1
Baseline: Extreme anxious/depress3.55.2
Week 13: Not anxious/depress53.652.4
Week 13: Moderate anxious/depress43.444.0
Week 13: Extreme anxious/depress3.03.7
Week 25: No anxious/depress55.555.5
Week 25: Moderate anxious/depress41.941.8
Week 25: Extreme anxious/depress2.52.7
EOT: Not anxious/depress58.558.3
EOT: Moderate anxious/depress38.939.1
EOT: Extreme anxious/depress2.62.6
FU Month 18: Not anxious/depress61.459.9
FU Month 18: Moderate anxious/depress36.237.0
FU Month 18: Extreme anxious/depress2.43.1
FU Month 24: Not anxious/depress63.861.0
FU Month 24: Moderate anxious/depress33.836.2
FU Month 24: Extreme anxious/depress2.42.8
FU Month 36: Not anxious/depress64.061.6
FU Month 36: Moderate anxious/depress33.335.4
FU Month 36: Extreme anxious/depress2.63.0
SecondaryTrough Serum Concentration (Cmin) of Pertuzumab
Time frame:
Cycles 1, 10 and 15 (Cycle length=21 days)
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Trough Serum Concentration (Cmin) of Pertuzumab
micrograms per milliliter (mcg/mL)Pertuzumab + Trastuzumab + Chemotherapy
Cycle 168.0 ± 16.6
Cycle 1088.1 ± 34.4
Cycle 1595.5 ± 51.5
SecondaryCmin of Trastuzumab
Time frame:
Cycles 1, 10 and 15 (Cycle length=21 days)
Reported as:
Mean · mcg/mL
Cmin of Trastuzumab
mcg/mLPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Cycle 132.1 ± 13.434.1 ± 11.4
Cycle 1065.0 ± 39.668.4 ± 23.0
Cycle 1572.9 ± 46.171.0 ± 30.4
SecondaryPeak Serum Concentration (Cmax) of Pertuzumab
Time frame:
Cycles 1, 10 and 15 (Cycle length=21 days)
Reported as:
Mean · mcg/mL
Peak Serum Concentration (Cmax) of Pertuzumab
mcg/mLPertuzumab + Trastuzumab + Chemotherapy
Cycle 1237 ± 118
Cycle 10222 ± 92.2
Cycle 15206 ± 94.9
SecondaryCmax of Trastuzumab
Time frame:
Cycles 1, 10 and 15 (Cycle length=21 days)
Reported as:
Mean · mcg/mL
Cmax of Trastuzumab
mcg/mLPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Cycle 1180 ± 81.0190 ± 51.6
Cycle 10219 ± 94.6225 ± 70.7
Cycle 15187 ± 95.1234 ± 73.5
PrimaryPercentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Percentage of participants with IDFS events (excluding SPNBC) is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (that is \[i.e.\], an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including ductal carcinoma in situ \[DCIS\] and lobular carcinoma in situ \[LCIS\]) and non-melanoma skin cancer were excluded as an event.

Time frame:
Randomization to the first occurrence of IDFS event (excluding SPNBC) (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Reported as:
Number · percentage of participants
Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings7.18.7
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Log Rank · p = 0.0446 (Statistical significance was controlled at a two-sided alpha level of 0.05.) · Hazard ratio (hr): 0.81 · 95% CI 0.66 to 1.00Hazard ratio was estimated by Cox regression.
PrimaryKaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings

Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (excluding SPNBC) at 3 years is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event.

Time frame:
3 years
Reported as:
Number · Estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Estimate of percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings94.06 (93.09 to 95.03)93.24 (92.21 to 94.26)

Adverse events

Collected over From randomization (for all-cause mortality) or first study treatment (for adverse events [AEs]) until the end of follow-up (up to 12.9 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab + Trastuzumab + Chemotherapy205/2,400 (8.5%)792/2,364 (33.5%)2,353/2,364 (99.5%)
Placebo + Trastuzumab + Chemotherapy247/2,404 (10.3%)686/2,405 (28.5%)2,374/2,405 (98.7%)
Most frequent serious events
Showing 10 of 528
Most frequent serious events
EventPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
FEBRILE NEUTROPENIABlood and lymphatic system disorders211/2364196/2405
DIARRHOEAGastrointestinal disorders58/236418/2405
PYREXIAGeneral disorders40/236446/2405
CARDIAC FAILURECardiac disorders44/236428/2405
NEUTROPENIABlood and lymphatic system disorders25/236434/2405
PNEUMONIAInfections and infestations19/236427/2405
VOMITINGGastrointestinal disorders19/236415/2405
DEHYDRATIONMetabolism and nutrition disorders19/23645/2405
NAUSEAGastrointestinal disorders18/236414/2405
CELLULITISInfections and infestations15/236413/2405
Most frequent other events
Showing 10 of 72
Most frequent other events
EventPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
DIARRHOEAGastrointestinal disorders1667/23641091/2405
NAUSEAGastrointestinal disorders1639/23641582/2405
ALOPECIASkin and subcutaneous tissue disorders1594/23641635/2405
FATIGUEGeneral disorders1160/23641074/2405
ARTHRALGIAMusculoskeletal and connective tissue disorders765/2364867/2405
VOMITINGGastrointestinal disorders771/2364727/2405
CONSTIPATIONGastrointestinal disorders692/2364762/2405
MYALGIAMusculoskeletal and connective tissue disorders620/2364716/2405
ANAEMIABlood and lymphatic system disorders667/2364567/2405
STOMATITISGastrointestinal disorders666/2364574/2405

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants regardless of treatment received.

Age, Continuous
Age, Continuous(years)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
Mean51.7 ± 10.951.4 ± 10.751.5 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
Female239723964793
Male3811
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
Hispanic or Latino454287
Not Hispanic or Latino432386818
Unknown or Not Reported192319763899
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
White170516943399
Black324173
Asian5905981188
Other6669135
Not reported729
Nodal Status
Nodal Status(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
0 Positive Nodes and Tumor ≤1 cm9084174
0 Positive Nodes and Tumor >1 cm8078181625
1 to 3 Positive Nodes9079001807
≥4 Positive Nodes5966021198
Adjuvant Chemotherapy Regimen
Adjuvant Chemotherapy Regimen(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
Anthracycline containing regimen186518773742
Non-anthracycline containing regimen5355271062
Hormone Receptor Status
Hormone Receptor Status(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
Negative (ER and PgR negative)8648581722
Positive (ER and/or PgR positive)153615463082
Protocol Version at Enrollment
Protocol Version at Enrollment(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
Protocol Version A182818273655
Protocol Version B5725771149
08

Study locations

546 sites
  • HonorHealth Research Institute ? Bisgrove
    Scottsdale, Arizona 85258, United States
  • Providence Regional Medical Center
    Everett, California 98208, United States
  • Marin Cancer Care Inc
    Greenbrae, California 94904, United States
  • Kaiser Permanente - Hayward
    Hayward, California 94545, United States
  • UCSD Moores Cancer Center
    La Jolla, California 92093, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Kaiser Permanente - Oakland
    Oakland, California 94611, United States
  • Kaiser Permanente - Roseville
    Roseville, California 95661, United States
  • Sutter Cancer Center
    Sacramento, California 95816, United States
  • Kaiser Permanente Sacramento Medical Center
    Sacramento, California 95825, United States
  • Southern California Kaiser Permanente
    San Diego, California 92108, United States
  • K. Permanente - San Fransisco
    San Francisco, California 94115, United States
  • K. Permanente - San Jose
    San Jose, California 95119, United States
  • K. Permanente - Santa Clara
    Santa Clara, California 95051, United States
  • K. Permanente - S. San Fran
    South San Francisco, California 94080, United States
  • Kaiser Permanente
    Vallejo, California 94589, United States
  • K. Permanente - Walnut Creek
    Walnut Creek, California 94596, United States
  • Rocky Mountain Cancer Center - Denver
    Denver, Colorado 80220, United States
  • Lutheran Hematology &Oncology
    Wheat Ridge, Colorado 80033, United States
  • Eastern Ct Hema/Onco Assoc
    Norwich, Connecticut 06360, United States
  • Washington Cancer Institute at MedStar Washington Hospital Center.
    Washington D.C., District of Columbia 20010, United States
  • Georgetown U
    Washington D.C., District of Columbia 20057, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • Memorial Cancer Institute
    Hollywood, Florida 33021, United States
  • Mayo Clinic-Jacksonville
    Jacksonville, Florida 32224, United States
  • Cancer Specialists
    Jacksonville, Florida 32256, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Memorial Breast Cancer Center
    Pembroke Pines, Florida 33028, United States
  • Hematology Oncology Associates of the Treasure Coast
    Port Saint Lucie, Florida 34952, United States
  • Florida Cancer Specialists
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists, Research Department
    West Palm Beach, Florida 33401, United States
  • Phoebe Putney Memorial Hospital
    Albany, Georgia 31701, United States
  • Georgia Cancer Specialists
    Atlanta, Georgia 30341, United States
  • Northwest Georgia Oncology Centers PC - Marietta
    Marietta, Georgia 30060, United States
  • Kootenai Cancer Center
    Post Falls, Idaho 83854, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Uni of Chicago
    Chicago, Illinois 60637, United States
  • Ingalls Memorial Hospital
    Harvey, Illinois 60426, United States
  • Loyola University Med Center
    Maywood, Illinois 60153, United States
  • Edward Cancer Center Naperville
    Naperville, Illinois 60540, United States
  • Illinois Cancer Care
    Peoria, Illinois 61615-7828, United States
  • Edward Cancer Center Plainfield
    Plainfield, Illinois 60585, United States
  • Quincy Medical Group
    Quincy, Illinois 62301, United States
  • Carle Foundation
    Urbana, Illinois 61801, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214-3728, United States
  • Cancer Center of Acadiana at Lafayette General
    Lafayette, Louisiana 70503, United States
  • Cancer Care of Maine
    Bangor, Maine 04401, United States
  • New England Cancer Specialists
    Scarborough, Maine 04074, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Weinberg CA Inst Franklin Sq
    Baltimore, Maryland 21237, United States
  • Maryland Oncology & Hematology, PA
    Bethesda, Maryland 20817, United States
  • Massachusetts General Hospital.
    Boston, Massachusetts 02114, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Beth Israel Deac Med Ctr
    Boston, Massachusetts 02215, United States
  • Dana Farber Can Ins
    Boston, Massachusetts 02215, United States
  • Berkshire Hematology, Oncology Pc
    Pittsfield, Massachusetts 01201, United States
  • Grand Rapids Clinical Oncology Program
    Grand Rapids, Michigan 49503, United States
  • West Michigan Cancer Center
    Kalamazoo, Michigan 49007, United States
  • Southdale Cancer Clinic
    Edina, Minnesota 55414, United States
  • Coborn Cancer Center
    Saint Cloud, Minnesota 56303, United States
  • Metro-Minnesota Community Oncology Research Consortium
    Saint Louis Park, Minnesota 55416, United States
  • Jackson Oncology Associates, PLLC
    Jackson, Mississippi 39202, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Heartland CCOP/Missouri Baptist Medical Center
    St Louis, Missouri 63131, United States
  • Cancer Alliance of Nebraska
    Lincoln, Nebraska 68510, United States
  • Cancer Alliance of Nebraska
    Omaha, Nebraska 68106, United States
  • Dartmouth Hitchcock Med Center
    Lebanon, New Hampshire 03756, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey 07039, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12206, United States
  • Roswell Park Cancer Inst.
    Buffalo, New York 14263, United States
  • Mount Sinai Beth Israel Medical Center
    New York, New York 10003, United States
  • Mount Sinai Beth Israel Comprehensive Cancer Center
    New York, New York 10011, United States
  • Mount Sinai West
    New York, New York 10019, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
  • University of North Carolina-Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Carolina Oncology Specialists, PA - Hickory
    Hickory, North Carolina 28602, United States
  • Oncology Hematology Care Inc
    Cincinnati, Ohio 45242, United States
  • The Mark H. Zangmeister Ctr
    Columbus, Ohio 43219, United States
  • Dayton Clinical Oncology Prog
    Dayton, Ohio 45420, United States
  • Toledo Clinic Cancer Center
    Toledo, Ohio 43623-3536, United States
  • Northwest Cancer Specialists - Portland (NE Hoyt St)
    Portland, Oregon 97213, United States
  • Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • Albert Einstein Healthcare Network
    Philadelphia, Pennsylvania 19141, United States
  • Magee Womens Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Charleston Oncology, P .A
    Charleston, South Carolina 29414, United States
  • Roper Bon Secours St. Francis Cancer Center
    Charleston, South Carolina 29414, United States
  • South Carolina Oncology Associates - SCRI
    Columbia, South Carolina 29210, United States
  • University of Missouri-Columbia
    Columbia, South Carolina 65203, United States
  • Cancer Centers of the Carolina
    Greenville, South Carolina 29615, United States
  • Sanford USD School of Medicine
    Sioux Falls, South Dakota 57104, United States
  • Tennessee Oncology , PLLC - Chattanooga
    Chattanooga, Tennessee 37403, United States
  • Tennessee Oncology - Nashville
    Nashville, Tennessee 37203, United States
  • Vanderbilt Breast Center at One Hundred Oaks
    Nashville, Tennessee 37204, United States
  • Texas Oncology-Medical City Dallas
    Dallas, Texas 75230, United States
  • Texas Oncology - DFW at Dallas Presbyterian Hospital
    Dallas, Texas 75231, United States
  • Texas Oncology - DFW
    Dallas, Texas 75246, United States
  • Texas Oncology-El Paso Cancer Treatment Center Grandview
    El Paso, Texas 79902, United States

Showing the first 100 of 546 sites across 42 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Agostinetto E, Gentile G, Samy F, Di Cosimo S, Aftimos P, Ponde N, Eiger D, Lambertini M, Cameron D, Kiermaier A, Bailey A, Viale G, Loi S, Piccart M, de Azambuja E. The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial. J Natl Cancer Inst. 2026 Apr 3:djag095. doi: 10.1093/jnci/djag095. Online ahead of print. PubMed 41934626 ↗
  • Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update. J Clin Oncol. 2024 Nov;42(31):3643-3651. doi: 10.1200/JCO.23.02505. Epub 2024 Sep 11. PubMed 39259927 ↗
  • de Azambuja E, Agostinetto E, Procter M, Eiger D, Ponde N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T; APHINITY Steering Committee and Investigators. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open. 2023 Feb;8(1):100772. doi: 10.1016/j.esmoop.2022.100772. Epub 2023 Jan 19. PubMed 36681013 ↗
  • Lambertini M, Fielding S, Loibl S, Janni W, Clark E, Franzoi MA, Fumagalli D, Caballero C, Arecco L, Salomoni S, Ponde NF, Poggio F, Kim HJ, Villarreal-Garza C, Pagani O, Paluch-Shimon S, Ballestrero A, Del Mastro L, Piccart M, Bines J, Partridge AH, de Azambuja E. Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. J Natl Cancer Inst. 2022 Aug 8;114(8):1117-1126. doi: 10.1093/jnci/djac096. PubMed 35512402 ↗
  • Gelber RD, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M; APHINITY Steering Committee and Investigators. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. Eur J Cancer. 2022 May;166:219-228. doi: 10.1016/j.ejca.2022.01.031. Epub 2022 Mar 18. PubMed 35313167 ↗
  • Bines J, Clark E, Barton C, Restuccia E, Procter M, Sonnenblick A, Fumagalli D, Parlier D, Arahmani A, Baselga J, Viale G, Reaby LL, Frank E, Gelber RD, Piccart M, Jackisch C, Petersen JA. Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. Br J Cancer. 2021 Jul;125(1):38-47. doi: 10.1038/s41416-021-01323-y. Epub 2021 Apr 7. PubMed 33828257 ↗
  • Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G, Thomssen C; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. J Clin Oncol. 2021 May 1;39(13):1448-1457. doi: 10.1200/JCO.20.01204. Epub 2021 Feb 4. PubMed 33539215 ↗
  • Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, Van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber RD, Piccart M, Mobus V, de Azambuja E; APHINITY Steering Committee and Investigators. Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clin Breast Cancer. 2020 Apr;20(2):174-181.e3. doi: 10.1016/j.clbc.2019.06.016. Epub 2019 Sep 5. PubMed 31924513 ↗
  • Luo Y, Li W, Jiang Z, Zhang Q, Wang L, Mao Y, Tjan-Heijnen VCG, Im SA, McConnell R, Bejarano S, Fumagalli D, Bines J, Wang B, Garg A, Kirschbrown WP, Xu B. Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. Anticancer Drugs. 2019 Sep;30(8):866-872. doi: 10.1097/CAD.0000000000000808. PubMed 31305270 ↗
  • Kirschbrown WP, Kagedal M, Wang B, Lindbom L, Knott A, Mack R, Monemi S, Nijem I, Girish S, Freeman C, Fumagalli D, McConnell R, Jerusalem G, Twelves C, Baselga J, von Minckwitz G, Bines J, Garg A. Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemother Pharmacol. 2019 Jun;83(6):1147-1158. doi: 10.1007/s00280-019-03826-1. Epub 2019 Apr 11. PubMed 30976844 ↗
  • von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. PubMed 28581356 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2011 to primary completion in Dec 2016, 61 months.

Results were first posted in Jan 2018, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 61 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2011
First posted
May 24, 2011
StartActual
Nov 8, 2011
Primary completionActual
Dec 19, 2016
CompletionActual
Nov 28, 2024
Results first posted
Jan 5, 2018
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01358877
Lead sponsor
Hoffmann-La Roche
Collaborators
Genentech, Inc., Breast International Group
Responsible party
Sponsor
First posted
May 24, 2011
Start date
Nov 8, 2011
Primary completion
Dec 19, 2016
Completion
Nov 28, 2024
Results posted
Jan 5, 2018
Last update
Nov 28, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion